December 2, 2021 – BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI) — a disease that is the result of malfunctioning valves and can lead to varicose veins.
Venclose is a leader in CVI treatment through its innovative Radio Frequency (RF) ablation technology platform designed for versatility, efficiency and simplicity. RF ablation is the predominant treatment of CVI and has wide acceptance among physicians.
The Venclose System is compactly designed and provides two heating length sizes (2.5 cm and 10 cm) in one 6 FR sized catheter. This dynamic dual heating length catheter provides multiple operational benefits to physicians.
With 30% more heating length than the longest leading competitive RF ablation catheter, the Venclose System can enable physicians to efficiently ablate more vein during each heating cycle and help to lower the total number of ablations required for in-vein treatment. The dual heating length means that physicians can ablate both long and short vein segments with the same catheter — reducing inventory management burden compared to catheters with shorter and/or static heating length sizes.
The system’s technology is also designed to help deliver a patient-centric approach to care. For example, its touchscreen display provides real-time procedure data to help inform physicians’ treatment decisions. The system also provides audible tones for thermal delivery.
Venclose was founded in 2014 to enhance the treatment of CVI through RF ablation technology. The company has since been committed to delivering technological advancements and procedural efficiencies to physicians treating CVI, while also helping to improve patient satisfaction. The Venclose System is currently available in a variety of healthcare settings across the U.S. and areas of Europe.
Terms of the transaction were not disclosed.